Is your child’s cancer resistant to treatment? Stand Up To Cancer (SU2C) is supporting a clinical trial that is seeking new ways to treat certain types of childhood cancers, called “hypermutant” cancers, for which there is currently no cure. The researchers believe these cancers could be very receptive to treatment with immune checkpoint inhibitors (ICI) such as nivolumab. Immunotherapy drugs like nivolumab work by “releasing the brakes” on the body’s immune system, and allowing it to fight against cancer.
This trial is seeking pediatric cancer patients who have either a hypermutant tumor or have Constitutional or Biallelic Mismatch Repair Deficiency (CMMRD or BMMRD) syndrome. Tumors will be biopsied and tested for hypermutation as part of the screening process.
This trial is seeking to:
- Identify hypermutant cancers
- Identify biomarkers that will predict which patients will respond to immunotherapy
- Test the responses to nivolumab, and to other drugs combined with nivolumab
The trial will be conducted internationally, in a total of four locations in Canada, the U.S., France and Israel.